{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'Apremilast remains under further clinical development for the treatment of inflammatory/', \"autoimmune disorders including Beh\u00e7et's disease and ulcerative colitis. Further studies within\", 'the approved indications of plaque psoriasis and psoriatic arthritis are also ongoing.', \"Please refer to the Investigator's Brochure (IB) for detailed information concerning the available\", 'pharmacology, toxicology, drug metabolism, clinical studies, and adverse event profile of the', 'investigational product (IP).', '1.3.', 'Rationale', '1.3.1.', 'Study Rationale and Purpose', 'Psoriasis vulgaris is a chronic inflammatory immunologic disorder which manifests primarily in', 'the skin. It is characterized by sharply demarcated areas of affected skin which appear thickened,', 'red, and scaly. The scalp, elbows, knees, lower back, hands, and feet are commonly affected', 'sites. About 80% of affected patients complain of pruritus (Gottlieb, 1998). The psoriatic', 'appearance of the skin is initiated by an APC - T-cell interaction leading to the release of', 'multiple inflammatory cytokines (Nestle, 2009). In time, this leads to an increased rate of', 'epidermal proliferation with impaired differentiation of keratinocytes, resulting in a thickened', 'epidermis covered by a thickened, parakeratotic stratum corneum. Dermal capillaries become', 'tortuous and dilated, and there is infiltration of both epidermis and dermis with immunologically', 'active cells (Lowes, 2007).', 'According to a European consensus statement on the definition of treatment goals for patients', 'with plaque psoriasis, mild psoriasis is defined as BSA < 10% and PASI < 10 and DLQI < 10.', 'However, many patients may present with BSA 10% and PASI 10 but due to the presence of', 'disease manifestations that are difficult to control with topical therapy alone, may have a', 'significantly impaired quality of life (DLQI > 10). These manifestations can include the', 'following: involvement of visible areas, involvement of major parts of the scalp, involvement of', 'genitals, involvement of palms and/or soles, onycholysis or onychodystrophy of at least two,', 'fingernails, pruritus leading to scratching, and presence of single recalcitrant plaques. The', 'presence of any of the previously mentioned manifestations may alter the classification of mild', 'psoriasis to moderate to severe psoriasis in need of systemic therapy due to significantly', 'impaired quality of life (Mrowietz, 2011).', '1.3.2.', 'Rationale for the Study Design', 'This is a Phase 4, multi-center, randomized, double-blind, placebo-controlled study to assess the', 'impact of apremilast on health-related quality of life, efficacy, and safety in patients with', 'manifestations of plaque psoriasis and impaired quality of life. The primary endpoint in this', 'study is the proportion of subjects who achieve a > 4-point change in the DLQI at Week 16', 'compared to placebo. The study population will be very heterogeneous and consist of subjects', 'with a variety of clinical manifestations of psoriasis, such as scalp, nail, palmoplantar, and', 'genital psoriasis and lesions in visible locations. Common among patients with any of these', 'manifestations is a high impairment in Quality of Life (QOL); therefore, assessing the proportion', 'of subjects who achieve a minimal clinically important difference in the DLQI is clinically', 'meaningful. Although the DLQI is the gold standard QOL assessment in psoriasis and other', 'dermatologic diseases, as a patient-reported outcome, it is often associated with a high placebo', 'Confidential and Proprietary', '18', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'response rate. To understand the true impact of apremilast on QOL in patients with', 'manifestations of psoriasis and impaired quality of life, a 16-week placebo-controlled period is', 'necessary. After Week 16, subjects who were randomized to placebo will receive active', 'treatment with apremilast through Week 52.', 'Confidential and Proprietary', '19', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']\n\n###\n\n", "completion": "END"}